The HIV-1 envelope glycoprotein (Env) trimer mediates cell entry and is
conformationally dynamic
1
–
8
. Imaging
by single-molecule fluorescence resonance energy transfer (smFRET) has revealed
that, on the surface of intact virions, mature pre-fusion Env transitions from a
pre-triggered conformation (state 1) through a default intermediate conformation
(state 2) to a conformation in which it is bound to three CD4 receptor molecules
(state 3)
8
–
10
. It is currently unclear how these
states relate to known structures. Breakthroughs in the structural
characterization of the HIV-1 Env trimer have previously been achieved by
generating soluble and proteolytically cleaved trimers of gp140 Env that are
stabilized by a disulfide bond, an isoleucine-to-proline substitution at residue
559 and a truncation at residue 664 (SOSIP.664 trimers)
5
,
11
–
18
.
Cryo-electron microscopy studies have been performed with C-terminally truncated
Env of the HIV-1
JR-FL
strain in complex with the antibody PGT151
19
. Both approaches have revealed similar
structures for Env. Although these structures have been presumed to represent
the pre-triggered state 1 of HIV-1 Env, this hypothesis has never directly been
tested. Here we use smFRET to compare the conformational states of Env trimers
used for structural studies with native Env on intact virus. We find that the
constructs upon which extant high-resolution structures are based predominantly
occupy downstream conformations that represent states 2 and 3. Therefore, the
structure of the pretriggered state-1 conformation of viral Env that has been
identified by smFRET and that is preferentially stabilized by many broadly
neutralizing antibodies—and thus of interest for the design of
immunogens—remains unknown.
The low-molecular-weight compound JRC-II-191 inhibits infection of HIV-1 by blocking the binding of the HIV-1 envelope glycoprotein gp120 to the CD4 receptor and is therefore an important lead in the development of a potent viral entry inhibitor. Reported here is the use of two orthogonal screening methods, GOLD docking and ROCS shape-based similarity searching, to identify amine-building blocks that, when conjugated to the core scaffold, yield novel analogues that maintain similar affinity for gp120. Use of this computational approach to expand SAR produced analogues of equal inhibitory activity but with diverse capacity to enhance viral infection. The novel analogues provide additional lead scaffolds for the development of HIV-1 entry inhibitors that employ protein-ligand interactions in the vestibule of gp120 Phe 43 cavity.
Efforts to develop therapeutic agents that inhibit HIV-1 entry have led to the identification of several small molecule leads. One of the most promising is the NBD series, which binds within a conserved gp120 cavity and possesses para-halogen substituted aromatic rings, a central oxalamide linker, and a tetramethylpiperidine moiety. In this study, we characterized structurally the interactions of four NBD analogues containing meta-fluoro substitution on the aromatic ring and various heterocyclic ring replacements of the tetramethylpiperidine group. The addition of a meta-fluorine to the aromatic ring improved surface complementarity and did not alter the position of the analogue relative to gp120. By contrast, heterocyclic ring replacements of the tetramethylpiperidine moiety exhibited diverse positioning and interactions with the vestibule of the gp120 cavity. Overall, the biological profile of NBD-congeners was modulated by ligand interactions with the gp120-cavity vestibule. Herein, six co-crystal structures of NBD-analogues with gp120 provide a structural framework for continued small molecule-entry inhibitor optimization.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.